The estimated Net Worth of Paul Gisbert Auwaerter is at least $20.9 Thousand dollars as of 6 October 2023. Paul Auwaerter owns over 5,000 units of Capricor Therapeutics Inc stock worth over $20,900 and over the last few years Paul sold CAPR stock worth over $0.
Paul has made over 1 trades of the Capricor Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Paul bought 5,000 units of CAPR stock worth $14,200 on 6 October 2023.
The largest trade Paul's ever made was buying 5,000 units of Capricor Therapeutics Inc stock on 6 October 2023 worth over $14,200. On average, Paul trades about 1,667 units every 0 days since 2023. As of 6 October 2023 Paul still owns at least 5,000 units of Capricor Therapeutics Inc stock.
You can see the complete history of Paul Auwaerter stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo..., and Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: